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"NY TWO PEOPLE can travel the same road 
ftand see different things. Thus, others discus-
sing the history of renal transplantation might have 
noted different landmarks. Valuable personal rem-
iniscences have been written by R.Y. CaIne of 
England l and J.E. Murray of Boston,2 whose ini-
tially separate careers came together in a remark-
able joint venture at Harvard in 1960. In addition, 
original articles, which are usually cited in histori-
cal reviews, but rarely read because of their inac-
cessibility, were republished recently in a volume 
of the Clio Chirurgica series. 3 Perusal of this ma-
terial gives unusual insight into the process of dis-
covery and development. Another prime source of 
historical information was published in 1972 by 
Professor Carl Groth, the Swedish transplantation 
surgeon who examined the medical literature from 
the crucial period of 1950 to 1970 and interviewed 
or corresponded with almost all of the physicians 
and surgeons who were working during this time. 4 
Kidney transplantation as a practical therapeutic 
option came from a series of steps that began to 
appear in the literature at the turn of this century. 
At first, the steps were small, widely spread in 
time, and often quixotic enough to be overlooked 
or condemned. As late as 1961, the Nobel Laure-
ate Macfarland Burnet wrote in the New England 
Journal of Medicine that" ... much thought has 
been given to ways by which tissues or organs not 
genetically and antigenically identical with the pa-
tient might be made to survive and function in the 
alien environment. On the whole, the present out-
look is highly unfavorable to success .... "5 This 
opinion was published on the eve of the successful 
clinical renal transplantations in 1962 and 1963 
that extended such procedures beyond the occa-
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sional identical and fraternal twin cases of the mid 
and late 1950s. These clinical trials in 1962 and 
1963 provoked editorials questioning the inherent 
feasibility of such efforts, as well as their ethical 
basis. 6 Yet, these trials were already late in a long, 
but at first slowly unfolding, story of whole organ 
transplantation, which was dominated by but not 
confined to the kidney. 
THE EARLIEST BEGINNINGS 
Heterotransplantation 
The first known attempts at clinical renal trans-
plantation by vascular anastomoses were made 
without immunosuppression between 1906 and 
1923 with pig, sheep, goat, and subhuman primate 
donors. The first of these efforts were in France? 
and Germany,8 but others followed as summarized 
elsewhere. 4.9 None of the kidneys functioned for 
long, if at all, and the human recipients died from 
a few hours to 9 days later. Although there was 
little or no understanding of the biologic barrier to 
success, some principles were clearly delineated. 
The applicability of vascular suture techniques, 
and even the possibility of using pelvic implanta-
tion sites, were either envisioned or actually prac-
ticed. No further renal heterotransplantations (ani-
mal to man) were tried again until 1963 when 
systematic and surprisingly successful clinical 
trials were made with chimpanzee9 and baboon 10.11 
kidneys. The eventual death of all of the recipients 
of animals organs ended renal heterotransplanta-
tion trials. 
Homotransplantation 
The first human to human kidney transplantation 
(homotransplantation) was reported in 1936 by the 
Russian, VoronoY,12 who transplanted a kidney 
from a cadaver donor of B + blood type to a recip-
ient of 0 + blood type in violation of what have 
become accepted rules of tissue transfer. 13 A 
further adverse factor was that the donor had been 
dead for 6 hours. The recipient died 48 hours later 
without making urine. 
Sporadic further efforts at renal homotransplan-
tation were made in the 20 ensuing years without 
effective immunosuppression as documented by 
Groth. 4 The heterotopic extraperitoneal technique 
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of renal transplantation that became today's stand-
ard was developed by the French surgeons Du-
bost, 14 Kuss, 15 and Servelle l6 and their associates. 
John Merrill, a Boston nephrologist, had seen the 
extraperitoneal operation while traveling in France 
in the early 1950s, as was mentioned by Hume et 
alY This technique was adapted for the histori-
cally important identical and fraternal twin cases 
in Boston.1 8.1 9 Today, variations of the operation 
shown in Fig I are used worldwide. 
As isolated events, or even in combination, 
none of the foregoing efforts would have had a 
major impact on medical practice. The principal 
ingredients of organ transplantation, namely im-
munosuppression, tissue matching, and organ pro-
curement (and preservation), were either unknown 
or so undeveloped that grafting of the kidney at a 
practical level was only a dream. Only two pa-
tients may have derived some benefit. The first ex-
ample of probable extended homograft function 
was in a patient of Lawler et al.2° The only other 
example of prolonged homograft function through 
1954 was in a nonimmunosuppressed patient of 
Hume et al 17 whose graft was placed in the thigh, 
with function for 5 months. 
($huwn 111--
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Fig 1. Extraperitoneal renal transplantation to 
pelvic site. (Reprinted with permission.38) 
549 
The Identical Twin Cases 
Two days before Christmas 1954. an identical 
twin transplantation was performed at the Peter 
Bent Brigham Hospital in Boston by the surgeons 
J.E. Murray and J.H. Harrison in collaboration 
with the nephrologist J.P. Merrill.2,18 They used 
the ectopic extraperitoneal technique originally 
described by the French surgeons. 14'16 The recipi-
ent survived for more than two decades. Living-
donor nephrectomy was an unusual operation at 
that time, and except for the ultimately unsuccess-
ful mother-to-offspring transplantation reported 
by Michon et al,21 it had been limited to the re-
moval of "expendable" kidneys excised during 
creation of ventriculoureteric cerebral spinal fluid 
shunts or for other reasons. No effort was made to 
preserve the excised identical twin kidney, which 
functioned promptly even though it underwent 82 
minutes of warm ischemia time. Merrill et aP8 
gave credit for originally suggesting the transplan-
tation to the recipients'S physician, David C. 
Miller of the Public Health Service Hospital, Bos-
ton. It was already known that skin grafts between 
identical twins were not rejected. 22 
The application of this information in the trans-
plantation of a vital organ was a bold extension of 
this principle and one that depended in the absence 
of immunosuppression on the perfect tissue match 
that could be obtained only with genetic identity of 
the donor and recipient. The efforts that were 
made to be sure of this condition were extraor-
dinary, and ultimately included skin grafting. 
Further progress in the presence of an immuno-
logic barrier would require effective immunosup-
pression. 
IMMUNOSUPPRESSION FROM 1959 to 1980 
Appreciation by Medawar23 that rejection is an 
immunologic phenomenon made inevitable almost 
everything that followed. By 1960, the possibility 
of weakening the recipient immune system in or-
der to mitigate rejection had been established in 
animals with corticosteroids,24 total body irradia-
tion,2526 and the cytotoxic drug 6-mercapto-
purine2730 or its imidazole derivative, azathio-
prine. 31 However, prolonged survival of skin or 
kidney grafts in experimental animals was a rela-
tively uncommon achievement. Sporadic attempts 
to use these techniques for renal homotransplanta-
tion in humans were so unsuccessfu141932,34 that it 
was widely thought that the immunosuppression 
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requisite to prevent rejection would inevitably lead 
to immunologic invalidism and lethal infections. 
There are no surviving patients from the era pre-
ceding 1962 during which immunosuppression 
usually was provided by total body irradiation 
(Table 1). However, the long survival of two fra-
ternal twin recipients studied during this earlier 
period provided an exceptional incentive for con-
tinuing efforts during an otherwise bleak time. 
The first of these irradiated fraternal (nonidenti-
cal) twins, received his brother's kidney in Boston 
on January 24, 1959. 19,32,35 He died in August 
1979 of arteriosclerotic heart disease (personal 
communication, Robert Kirkman, August 1989). 
The second irradiated fraternal twin was trans-
planted in Paris on June 29, 1959,36 and died on 
July 13, 1985 of carcinoma of the bladder (per-
sonal communication, Henri Kreis, August 1989). 
Although a few patients treated in 1960 and 1961 
in Paris and Boston with 6-mercaptopurine or 
azathioprine with or without irradiation had ex-
tended survival, they also died within 18 months. 
One of the Boston cadaveric kidney recipients, a 
patient of Murray and Merrill, was the first to 
have extended survival under drug therapy only. 33 
The pessimism that resulted from these clinical 
trials was changed drastically in 1962 and 1963 
when it was discovered at the University of Col-
orado that azathioprine and prednisone had at least 
additive, and probably synergistic, effects which 
allowed the prevention or reversal of renal homo-
graft rejection in most clinical cases. 37 The impe-
tus given to renal transplantation as this informa-
tion became known was reflected in the startling 
proliferation of centers in 1962 to 1964. 
Considering the end of this explosive new phase 
as March 1964 was natural. The 64 cases accumu-
Table 1. PrinCipal Immunosuppressive Regimens 
Used for Clinical Kidney Transplantation 
Year 
Agents Reported Place Reference 
Total body irradiation 1960 Boston 19,35 
Azathioprine 1962 Boston 32,33 
Azathioprine-steroids 1963 Denver 37 
Antilymphoid globulin 
(ALG) as adjunct* 1966 Denver 42 
Cyclosporine 1978-1979 Cambridge 47 
Cyclosporine-steroids 1980 Denver 50 
FK 506 1989 Pittsburgh 57 
* Polyclonal ALG has been largely replaced by mono-
clonal anti-T-lymphocy1e antibodies45 
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lated by that time at the University of Colorado 
provided the basis for the first textbook on renal 
transplantation. 38 This same time frame was used 
to collect all 342 renal homotransplants performed 
in the world. 39 The impetus for this extraordinary 
compilation came from Joseph E. Murray of Bos-
ton, following a conference sponsored by the Na-
tional Research Council and the National Acad-
emy of Sciences on September 26 and 27, 1963 in 
Washington, DC. About 25 early workers (sur-
geons, physicians, and pathologists) who had con-
tributed to the embryonal new specialty of renal 
transplantation were the participants. 
The meticulousness of the first registry report39 
made it possible 25 years later in the summer of 
1989 to trace the fate of all non-twin kidney recipi-
ents who had been alive at the end of March 
1964. 40 There were 24 25-year survivors, of 
whom 15 were from the original Colorado series. 
Nine were still alive at six other centers (Table 2). 
These included three of David Hume's original pa-
tients at the Medical College of Virginia. 41 
It is noteworthy that none of the world's 24 
quarter-century survivors had been given an unre-
lated donor kidney. Nor was there an example in 
the world of a 25-year survival of a cadaver donor 
kidney allograft at the time of this report. 40 A ca-
daver recipient in Paris who had maintained per-
fect renal function was expected to pass this bar-
rier on October 12, 1989 (personal 
communication, Henri Kreis, August 1989). This 
French recipient was 31 years old at the time of 
Table 2. 2S-Year Survivors (Non-Twin) From 
Era Before March 31, 1964 
Original Program 
No, Grafts Chief 
University of Colorado' 15 11 Thomas Starzl 
Medical College of 
Virginia (Richmond) 3 3 David Hume 
University of Minnesota 2 2 William Kelly 
Necker Hospital (Paris) 0 Jean Hamburger 
Peter Bent Brigham 
Hospital (Boston) 1 Joseph Murray 
Western Infirmary 0 Michael Woodruff 
(Edinburgh) 
Cleveland Clinic Wilhelm Kollf 
Total 24 18 
NOTE: Full documentation in reference 40. 
• Fourteen of these patients are still alive after 26 to 29 
years. The other died of a myocardial infarction in postop-
erative year 26. 
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her transplantation in 1964 under the care of Pro-
fessor Jean Hamburger. 
Because of dissatisfaction with azathioprine-
prednisone therapy, particularly for cadaveric re-
nal transplantation, modifications of or additions 
to the original double-drug treatment were made 
during the next 16 years (Table 1). Most of the 
modifications were designed to blunt the attack of 
the lymphocytes, which had been recognized as 
the mediators of rejection. The most significant 
addition was antilymphocyte globulin (ALG), 
which was used as an adjunct to azathioprine and 
prednisone. 42 ALG consisted of polyclonal anti-
bodies raised in horses, rabbits, goats, or other 
animals by immunizing them to human lympho-
cytes. 43 When thymic lymphocytes were used for 
immunization, the product was called antithymo-
cyte globulin (ATG). The active ')I-globulin was 
extracted, purified, and made ready for intramus-
cular or intravenous use. Usually, ALG was ad-
ministered during the first few weeks or months 
after transplantation. Alternatively, it was used for 
the specific indication of rejection. 
In spite of its great potential value, polyclonal 
ALG was not universally employed as a part of the 
antirejection armamentarium because of severely 
limiting features, including its inability to be 
standardized. 43 This latter problem and other defi-
ciencies were eliminated with the hybridoma tech-
nology introduced by Kohler and Milstein. 44 With 
hybridoma cells injected into the peritoneum of 
mice, a homogeneous (monoclonal) antihuman-
lymphocyte antibody could be produced. Therapy 
with monoclonal antibodies was introduced into 
clinical medicine by Cosimi et al45 using the so-
called OKT3 antibodies, which selectively deplete 
mature T lymphocytes. Their prime objective was 
to reverse kidney graft rejection that was nonre-
sponsive or poorly responsive to conventional cor-
ticosteroid therapy and azathioprine. OKT3 
therapy has been proved to be of value clinically, 
and it was released in 1986 for general use in the 
United States by the Food and Drug Administra-
tion (FDA). There has been much interest subse-
quently in even more specific monoclonal anti-
bodies that target highly specific subpopulations of 
lymphocytes. 
In spite of what had been achieved by 1978 with 
most of the foregoing drugs and drug combina-
tions, renal transplantation remained an unpredict-
able and dangerous undertaking, especially if ca-
----~---~-K----- .. --------------
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daver donors were used. The margin between 
effective and toxic immunosuppression was too 
narrow. Consequently, the field of transplantation 
had a relative growth arrest throughout the 1970s, 
and there seemed to be little hope of major im-
provement. The clinical transplant sessions at sci-
entific society meetings had become tedious expo-
sitions in which claims of results, counterclaims, 
and shuffling of details of management filled the 
programs. The boredom was relieved with the ar-
rival of cyclosporine. 
IMMUNOSUPPRESSION IN THE 19805 
The immunosuppressive qualities of the fungus 
extract cyclosporine were delineated by Borel et 
al46 of Switzerland, and the first clinical trials for 
solid organ transplantation were performed by 
CaIne and his associated in Cambridge, England, 
beginning in the spring of 1978.41 There was a 
high mortality in the 1978 to 1979 trials at Cam-
bridge, using cyclosporine with other drugs, and 
three of the first 34 recipients developed lympho-
mas. CaIne recommended that cyclosporine be 
used alone for future trials. However, nephrotox-
icity almost invariably was observed at the doses 
that were required. The complications of cyclo-
sporine used with other agents were even more 
severe in further English trials of renal transplan-
tation by Sweny et al. 48 
Trials in the United States of cadaver renal trans-
plantation with cyclosporine were begun in late 
1979 at the Peter Bent Brigham Hospital in Boston 
and at the University of Colorado, Denver. Disap-
pointing results, no better than with azathioprine 
and prednisone, were reported from Boston using 
cyclosporine as the sole drug for the first two post-
operative months. 49 Case accrual was slow and 
only 16 patients had been treated with cyclospor-
ine at the Brigham by September 1981. In the 
other. and far more encouraging American trial, at 
the University of Colorado, cyclosporine was sys-
tematically combined with steroids. 50 The ability 
to control rejection of cadaver organs with this 
drug combination was greatly improved compared 
with any therapy in the past. Of equal importance, 
the maintenance steroid doses generally were low 
enough to allow survival with a considerable re-
duction in morbidity. By late May 1980, more than 
40 renal recipients of cadaver kidneys had been 
treated in Colorado. Later in 1980, two more 
American trials of cyclosporine-steroid therapy 
552 
were started in Minneapolis51 and Houston. 52 With 
the strategy of employing drug combinations with 
additive or synergistic immunosuppression, the 
doses of individual agents usually could be kept in 
the nontoxic range. Cyclosporine and steroids also 
have been combined in later years with azathio-
prine, and polyclonal or monoclonal ALG 
(OKT3). In November 1983, cyclosporine was re-
leased by the FDA for general use in the United 
States. 
By the time cyclosporine became generally 
available, the lymphomas that threatened the out-
look for cyclosporine at the outset were better un-
derstood. Similar lymphoproliferative tumors, 
earlier called reticulum cell sarcomas, had been 
seen frequently under azathioprine-steroid therapy 
with or without ALG.53 It was realized in the pa-
tients treated with cyclosporine that these lesions 
usually were caused by Epstein-Barr virus infec-
tions. By stopping or lightening immunosuppres-
sive therapy, most of the lesions melted away 
quickly without regard for their clonality.54 These 
observations removed the specter of an over-
whelming cyclosporine mortality caused by de 
novo lymphoid malignancies. 
The advent of cyclosporine improved the pros-
pects after living-related and especially cadaver 
renal transplantation. It also had an impact on 
transplantation of extrarenal organs. Cyclosporine 
changed liver and heart transplantation from ex-
otic experimental procedures to patient-service, 
and made possible the previously unattainable ob-
jectives of transplanting the heart and lungs, or 
single lungs. In spite of these attainments, better 
drugs and immunosuppressive techniques have 
been eagerly looked for because of the side effects 
of cyclosporine, of which the most serious have 
been nephrotoxicity, arterial hypertension, neuro-
toxicity, the production of diabetes mellitus, and 
cosmetic deformity from hirsutism, brutalization 
of the physiognomy in some children, gynecomas-
tia in men, and gum hyperplasia. 55 Most of these 
complications were already observed by CaIne by 
1980. 
A new drug called FK 506 was a product of this 
search. FK 506 was discovered in Japan by Kino et 
ars6 in 1984 during systematic screening for drugs 
with antimicrobial, antineoplastic, or immunosup-
pressive qualities. FK 506 has no structural simi-
larity to cyclosporine, but it has in common the 
ability to prevent T-Iymphocyte activation by in-
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hibiting the synthesis and expression of interleukin 
2 and other cytokines, including interferon 
gamma. It has been used clinically since February 
1989 for kidney, liver, heart, and lung recipi-
entsY·58 Because FK 506 appears to be less 
nephrotoxic than cyclosporine, has little effect on 
blood pressure, does not increase serum choles-
terol, and often can be used as monotherapy 
(without steroids), it seems destined to permit 
further improvements in the care of renal trans-
plant recipients in the 1990s. 
KIDNEY PROCUREMENT AND PRESERVATION 
The fact that Voronoy's first cadaver kidney 
donor (in 1936) had been dead for 6 hours illus-
trated the lack of insight 50 years ago about the 
requirements for successful organ preservation. 
The potential benefit of lowering the temperature 
of an excised organ was grasped instinctively by 
early workers. However, even such inefficient at-
tempts as surface cooling were not made in any of 
the identical twin renal transplantations performed 
through 1962. The infusion of a cold solution into 
its blood supply (core cooling) was a simple con-
cept that was introduced into the laboratory almost 
30 years ago to make possible liver transplantation 
in the dog. 59 Core cooling was later applied clini-
cally for transplantation of the kidney60 and even-
tually for all other organs. 
Today, the intraoperative infusion of cold fluids 
at the donor operation is the essential first step for 
effective organ removal and preservation. With all 
organs, the overriding objective is avoidance of 
warm ischemia. This is achieved by carefully 
timed in situ infusion of cold solutions into ana-
tomical regions, the limits of which are defined by 
preliminary dissection of the abdominal and/or 
thoracic aorta and cross clamping at those levels. 61 
Lactated Ringer's solution, the first infusate to 
be used,60 has a low potassium content and is 
nearly isotonic. Chilled special solutions with an 
electrolyte composition similar to that in cells 
were shown in 1969 by Collins et al 62 and by 
others to extend the permissible limit of cold renal 
ischemia beyond that achievable with isotonic so-
lutions. 
Preservation, which once seemed the compo-
nent of transplantation most susceptible to im-
provement, changed slowly over the years. The 
approach exemplified by the original contribution 
of Collins et al62 was to introduce novel ingre-
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dients into the solution, which stays in the cold 
devascularized organ during storage, or to use 
agents to minimize the reperfusion injury after re-
vascularization in the recipients. Then in 1987, 
Belzer and his associates63 introduced the Univer-
sity of Wisconsin (UW) solution for static (so-
called slush) storage. Among other constituents, 
the UW solution contains two sugars, lactobionate 
and raffinose, which prevent the imbibition of wa-
ter by parenchymal and other cells in the graft. 
There is more and more evidence that the graft 
microvasculature also is better preserved with UW 
solution than with past techniques, meaning that 
self-perpetuating injury is reduced after revascu-
larization in the recipient. The UW solution, 
which was first widely tested for liver transplanta-
tion, is a generic advance that has also had an im-
pact in renal transplantation. Now, kidneys can be 
preserved for 2 or 3 days with a high probability of 
prompt function. 
The alternative to these simple refrigeration 
techniques is continuous perfusion. Ackerman and 
Barnard64 of Capetown described perfusion with 
cold blood under hyperbaric oxygenation. A 
widely used perfusion technique for kidneys was 
described from San Francisco by Belzer et al,65 
using an asanguinous and oncotically controlled 
perfusate fluid. The method is a good one, but the 
quality of preservation in the first 2 days has not 
been markedly better than with the simpler and 
cheaper infusion and slush methods. 
No matter what the ultimate method of preserva-
tion, the first step is quick cooling of the kidneys, 
which usually are removed as part of the multiple 
graft procurement in "heart beating" cadaver 
donors. Until 1981, transplantation of the ex-
trarenal organs was a rare event. By late 1981, it 
had become obvious that liver and thoracic organ 
transplant procedures were going to be wide-
spread, and that a method of multiple organ pro-
curement would be required by which the kidneys, 
liver, heart, and lungs or various combinations of 
these organs could be removed without jeopardiz-
ing any of the individual organs. Such a system 
was developed at the Universities of Colorado and 
Pittsburgh, and aided by the efforts of the Surgeon 
General of the United States, C. Everett Koop, the 
technique was adopted as a worldwide standard al-
most overnight. 61 All organs to be used are cooled 
in situ, and after their cooling, they are rapidly 
removed by dissection in a bloodless field. The 
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sharing of organs from a common donor by recipi-
ent teams from widely separated centers became 
routine in the 1980s. 
TISSUE TYPING 
Antigen Matching 
Twenty-five years ago when the modern era of 
transplantation was in its infancy, it was predicted 
that tissue matching would have to be perfected if 
kidney grafting procedures were to succeed with 
any degree of reliability and predictability. The 
first prospective matching trials were started in 
1964 by Paul I. Terasaki of Los Angeles66,67 in col-
laboration with the University of Colorado trans-
plantation team. 
The results were disappointing. Since then, the 
validity of tissue matching, its genetic basis, and 
above all its complexity have become increasingly 
recognized. Although the value of tissue matching 
for transplantation between family members has 
been established, the complexity of the human his-
tocompatibility system has militated against easy 
matching between nonrelated people. Close 
matching for transplantation of the cadaver kidney 
has not commonly been achieved, and lesser de-
grees of matching have not correlated well with 
the outcome. Whether these expensive efforts at 
matching should continue has become a matter of 
public policy because of the increasing use by the 
United Network of Organ Sharing (UNOS) of tis-
sue matching as the overriding determinant of ca-
daver kidney distribution nationally. The inexpli-
cable paradox continues of reports from two 
multicenter case compilations (one American and 
one European) having an overlapping data base 
which claim a slight but significant gain in survival 
of well-matched versus mismatched cadaver kid-
neys, whereas almost none of the major centers or 
consortia which contribute to these data pools are 
able to see this trend in their own material. HLA 
matching has faded as a factor in transplantation, 
because the results with modern day immunosup-
pression are almost as good with unmatched ca-
daveric kidneys as with kidneys from well-
matched blood relatives. 
Cross-Matching 
The importance of the cross-match concept re-
mains undiminished 25 years after its description. 
None of the immunosuppressive measures availa-
ble today can prevent the immediate destruction of 
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kidneys by preformed humoral antibodies in what 
has been called "hyperacute rejection." In 1965, 
Terasaki et al66 described the first example of this 
phenomenon. Kissmeyer-Nielsen et al,68 Williams 
et al,69 and numerous other observers7o have made 
valuable observations about hyperacute rejection, 
but except for its variable association with pre-
formed antigraft antibodies, its exact pathogenesis 
is not understood. The process of sudden graft in-
farction with this kind of rejection is caused by 
occlusion of the graft microvasculature with 
formed blood elements and clot, presumably fol-
lowing an antigen-antibody reaction, which is not 
always measurable. 71 Hyperacute rejection 
usually, but not always, can be avoided by the 
cross-match test, which detects antidonor cyto-
toxic antibodies in the recipient serum in advance 
of operation. Understanding and prevention of hy-
peracute rejection could hold the key to successful 
heterotransplantation. 
THOMAS E. STARZL 
THE EFFECT OF 
TRANSPLANTATION ON NEPHROLOGY 
Renal transplantation and nephrology came 
from the same mother and father (medicine and 
surgery), were raised in the same crib, survived 
sibling rivalries, and finally came to peace with 
each other. Eventually, the practice of nephrology 
was revolutionized by transplantation and vice 
versa. As great as it has been, the full impact of the 
relationship has yet to be felt. The immunosup-
pression that gives transplantation its specificity 
has become, or promises to be, so powerful and 
highly focused on discrete components of the im-
mune apparatus that many of the diseases lead-
ing to transplantation, including autoimmune 
nephritides and diabetes mellitus, could be inter-
dicted in the near future by treatment similar to 
that used to prevent graft rejection. 
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